Limits...
A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and (99m)Tc-MDP whole-body bone scanning for imaging osteolytic bone metastases.

Zhang L, Chen L, Xie Q, Zhang Y, Cheng L, Li H, Wang J - BMC Med Imaging (2015)

Bottom Line: The sensitivity, specificity, and accuracy with respect to the diagnosis of osteolytic bone metastases and bone lesions were compared between the two imaging methods.It was found that (99m)Tc-MDP whole-body BS could discriminate between patients with 50.2% (95% CI, 45.4-55.1%) sensitivity, 50.0% (95% CI, 18.8-81.2%) specificity, and 50.2% (95% CI, 45.5-55.1%) accuracy. 18F-FDG PET/CT achieved higher sensitivity, specificity, and accuracy in detecting osteolytic bone metastases than 99mTc-MDP whole-body BS (p<0.001).F-FDG PET/CT has a higher diagnostic value than (99m)Tc-MDP whole-body BS in the detection of osteolytic bone metastases, especially in the vertebra.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China. linzhangswh@yahoo.com.

ABSTRACT

Background: The objective of this study was to evaluate the feasibility and diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and (99m)Tc-methylenediphosphonate (MDP) whole-body bone scanning (BS) for the detection of osteolytic bone metastases.

Methods: Thirty-four patients with pathologically confirmed malignancies and suspected osteolytic bone metastases underwent 18F-FDG PET/CT and (99m)Tc-MDP whole-body BS within 30 days. The sensitivity, specificity, and accuracy with respect to the diagnosis of osteolytic bone metastases and bone lesions were compared between the two imaging methods.

Results: The sensitivity, specificity, and accuracy of 18F-FDG PET/CT for the diagnosis of osteolytic bone metastases were 94.3% (95% confidence interval [CI], 91.6-96.2%), 83.3% (95% CI, 43.6-96.9%), and 94.2% (95% CI, 91.5-96.1%), respectively. It was found that (99m)Tc-MDP whole-body BS could discriminate between patients with 50.2% (95% CI, 45.4-55.1%) sensitivity, 50.0% (95% CI, 18.8-81.2%) specificity, and 50.2% (95% CI, 45.5-55.1%) accuracy. 18F-FDG PET/CT achieved higher sensitivity, specificity, and accuracy in detecting osteolytic bone metastases than 99mTc-MDP whole-body BS (p<0.001).

Conclusions: F-FDG PET/CT has a higher diagnostic value than (99m)Tc-MDP whole-body BS in the detection of osteolytic bone metastases, especially in the vertebra.

Show MeSH

Related in: MedlinePlus

Flow chart of the study profile according to the18F-FDG PET-CT and 99mTc-MDP whole-body bone scanning findings.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4358702&req=5

Fig1: Flow chart of the study profile according to the18F-FDG PET-CT and 99mTc-MDP whole-body bone scanning findings.

Mentions: The Medical Research Ethics Committee of the Third Military Medical University (Chongqing, China) reviewed and approved the present study. Informed consent was not required for this retrospective study. A total of 356 patients were examined using PET/CT between January 2009 and December 2012, and those meeting the following inclusion criteria were recruited to the study: had pathologically and follow-up confirmed malignancies and concurrent suspected osteolytic bone metastases; had no treatment before imaging; and had undergone PET/CT and 99mTc-MDP BS procedures within 30 days of each other. A total of 34 patients (22 were male and 12 were female) were included in the study (FigureĀ 1). In total, there were 21 cases of lung cancer, five cases of unknown primary tumor, two cases of lymphoma, and one case each of sarcoma, prostatic carcinoma, thyroid carcinoma, hepatoma, esophageal cancer, and gastric carcinoma.Figure 1


A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and (99m)Tc-MDP whole-body bone scanning for imaging osteolytic bone metastases.

Zhang L, Chen L, Xie Q, Zhang Y, Cheng L, Li H, Wang J - BMC Med Imaging (2015)

Flow chart of the study profile according to the18F-FDG PET-CT and 99mTc-MDP whole-body bone scanning findings.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4358702&req=5

Fig1: Flow chart of the study profile according to the18F-FDG PET-CT and 99mTc-MDP whole-body bone scanning findings.
Mentions: The Medical Research Ethics Committee of the Third Military Medical University (Chongqing, China) reviewed and approved the present study. Informed consent was not required for this retrospective study. A total of 356 patients were examined using PET/CT between January 2009 and December 2012, and those meeting the following inclusion criteria were recruited to the study: had pathologically and follow-up confirmed malignancies and concurrent suspected osteolytic bone metastases; had no treatment before imaging; and had undergone PET/CT and 99mTc-MDP BS procedures within 30 days of each other. A total of 34 patients (22 were male and 12 were female) were included in the study (FigureĀ 1). In total, there were 21 cases of lung cancer, five cases of unknown primary tumor, two cases of lymphoma, and one case each of sarcoma, prostatic carcinoma, thyroid carcinoma, hepatoma, esophageal cancer, and gastric carcinoma.Figure 1

Bottom Line: The sensitivity, specificity, and accuracy with respect to the diagnosis of osteolytic bone metastases and bone lesions were compared between the two imaging methods.It was found that (99m)Tc-MDP whole-body BS could discriminate between patients with 50.2% (95% CI, 45.4-55.1%) sensitivity, 50.0% (95% CI, 18.8-81.2%) specificity, and 50.2% (95% CI, 45.5-55.1%) accuracy. 18F-FDG PET/CT achieved higher sensitivity, specificity, and accuracy in detecting osteolytic bone metastases than 99mTc-MDP whole-body BS (p<0.001).F-FDG PET/CT has a higher diagnostic value than (99m)Tc-MDP whole-body BS in the detection of osteolytic bone metastases, especially in the vertebra.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China. linzhangswh@yahoo.com.

ABSTRACT

Background: The objective of this study was to evaluate the feasibility and diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and (99m)Tc-methylenediphosphonate (MDP) whole-body bone scanning (BS) for the detection of osteolytic bone metastases.

Methods: Thirty-four patients with pathologically confirmed malignancies and suspected osteolytic bone metastases underwent 18F-FDG PET/CT and (99m)Tc-MDP whole-body BS within 30 days. The sensitivity, specificity, and accuracy with respect to the diagnosis of osteolytic bone metastases and bone lesions were compared between the two imaging methods.

Results: The sensitivity, specificity, and accuracy of 18F-FDG PET/CT for the diagnosis of osteolytic bone metastases were 94.3% (95% confidence interval [CI], 91.6-96.2%), 83.3% (95% CI, 43.6-96.9%), and 94.2% (95% CI, 91.5-96.1%), respectively. It was found that (99m)Tc-MDP whole-body BS could discriminate between patients with 50.2% (95% CI, 45.4-55.1%) sensitivity, 50.0% (95% CI, 18.8-81.2%) specificity, and 50.2% (95% CI, 45.5-55.1%) accuracy. 18F-FDG PET/CT achieved higher sensitivity, specificity, and accuracy in detecting osteolytic bone metastases than 99mTc-MDP whole-body BS (p<0.001).

Conclusions: F-FDG PET/CT has a higher diagnostic value than (99m)Tc-MDP whole-body BS in the detection of osteolytic bone metastases, especially in the vertebra.

Show MeSH
Related in: MedlinePlus